Abstract
Background: Real-life data often highlight the side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective: To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL-17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants. Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3–4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis.
Lingua originale | English |
---|---|
pagine (da-a) | 665-672 |
Numero di pagine | 8 |
Rivista | Expert Opinion on Biological Therapy |
Volume | 20 |
DOI | |
Stato di pubblicazione | Pubblicato - 2020 |
Keywords
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
- Drug Eruptions
- Female
- Humans
- IL17
- Interleukin-17
- Male
- Middle Aged
- Psoriasis
- Retrospective Studies
- Skin
- Steroids
- Young Adult
- anti IL17
- eczematous reactions
- ixekizumab
- secukinumab
- side effects